References

References:

  1. Chandra A, Crothers B, Kurtycz D, et al. The International System for Serous Fluid Cytopathology. Cham, Switzerland: Springer Nature, 2020.
  2. Dermawan JKT, Policarpio-Nicolas ML. Malignancies in Pleural, Peritoneal, and Pericardial Effusions. Arch Pathol Lab Med. 2020; 144: 1086-1091.
  3. Cibas E, Ducatman B. Cytology: Diagnostic Principles and Clinical Correlates. New York, NY: Elsevier Health Sciences Division, 2021.
  4. Farahani SJ, Baloch Z. Are we ready to develop a tiered scheme for the effusion cytology? A comprehensive review and analysis of the literature. Diagn Cytopathol. 2019; 47: 1145-1159.
  5. Pinto D, Schmitt F. Current applications of molecular testing on body cavity fluids. Diagn Cytopathol. 2020; 48: 840-851.
  6. Sundling KE, Cibas ES. Ancillary studies in pleural, pericardial, and peritoneal effusion cytology. Cancer Cytopathol. 2018; 126 Suppl 8: 590-598.
  7. Yu GH, Glaser LJ, Gustafson KS. Role of Ancillary Techniques in Fluid Cytology. Acta Cytol. 2020; 64: 52-62.
  8. Hida T, Hamasaki M, Matsumoto S, et al. Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry. Lung Cancer 2017; 104: 98-105.
  9. Walts AE, Hiroshima K, McGregor SM, et al. BAP1 Immunostain and CDKN2A (p16) FISH Analysis: Clinical Applicability for the Diagnosis of Malignant Mesothelioma in Effusions. Diagn Cytopathol. 2016; 44: 599-606.
  10. Mangla G, Bakshi P, Agarwal P, et al. Diagnostic Utility of Claudin4 and Comparison with BerEp4 as a Marker for Metastatic Adenocarcinoma in Serous Effusions. Acta Cytol. 2023; 67: 564-572.
  11. Sahu S, Sharma S, Gupta P, et al. MOC31 Immunostaining in the Diagnosis of Metastatic Adenocarcinoma in Serous Fluid: Special Emphasis on Atypical Cytological Cases. Acta Cytol. 2021; 65: 242-249.
  12. Bernardi L, Bizzarro T, Pironi F, et al. The "Brescia panel" (Claudin-4 and BRCA-associated protein 1) in the differential diagnosis of mesotheliomas with epithelioid features versus metastatic carcinomas. Cancer Cytopathol. 2021; 129: 275-282.
  13. Rossi G, Murer B, Cavazza A, et al. Primary mucinous (so-called colloid) carcinomas of the lung: a clinicopathologic and immunohistochemical study with special reference to CDX-2 homeobox gene and MUC2 expression. Am J Surg Pathol. 2004; 28: 442-452.
  14. Rossi G, Cavazza A, Righi L, et al. Napsin-A, TTF-1, EGFR, and ALK Status Determination in Lung Primary and Metastatic Mucin-Producing Adenocarcinomas. Int J Surg Pathol. 2014; 22: 401-407.
  15. Nelson ER, Sharma R, Argani P, et al. Utility of Sox10 labeling in metastatic breast carcinomas. Hum Pathol. 2017; 67: 205-210.
  16. Ai D, Yao J, Yang F, et al. TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Mod Pathol. 2021; 34: 710-719.
  17. Wolff AC, Hammond MEH, Allison KH, et al. HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary. J Oncol Pract. 2018; 14: 437-441.
  18. Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol. 2020; 38: 1346-1366.
  19. Nakayama Y, Nakagomi H, Omori M, et al. Benefits of using the cell block method to determine the discordance of the HR/HER2 expression in patients with metastatic breast cancer. Breast Cancer 2016; 23: 633-639.
  20. Gurel B, Ali TZ, Montgomery EA, et al. NKX3.1 as a marker of prostatic origin in metastatic tumors. Am J Surg Pathol. 2010; 34: 1097-1105.
  21. Genega EM, Ghebremichael M, Najarian R, et al. Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade. Am J Clin Pathol. 2010; 134: 873-879.
  22. Wang Q, Reid MD. Cytopathology of solid pancreatic neoplasms: An algorithmic approach to diagnosis. Cancer Cytopathol. 2022; 130: 491-510.